SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

SANES

10.429

-1.21%↓

BBVA

18.95

-0.01%↓

CABK

10.812

-1.19%↓

INGA

25.52

-0.87%↓

NDA.FI

15.57

-1.89%↓

Home・Elenco Azioni・Bayer AG

Bayer AG

Chiusa

SettoreFinanza

36.945 -1.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.92

Massimo

37.18

Metriche Chiave
By Trading Economics
Entrata	-2.8B -3.8B
Vendite	1.8B 11B
EPS	-3.82
Rendimento da dividendi	0.29
Margine di Profitto	-32.847
Dipendenti	87,280
EBITDA	1.4B 2B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+29.31% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.29% 4.62%
Utili prossimi	12 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3.2B 37B
Apertura precedente	38.22
Chiusura precedente	36.945

Notizie sul Sentiment di mercato

By Acuity

78%

22%

412 / 439 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

22.99 / 23.88 Supporto e resistenza

Bayer AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mag 2026, 10:51 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 mag 2026, 07:01 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

4 mar 2026, 11:06 UTC

Utili

Bayer Net Loss Widens on Weedkiller Litigation Charges -- 2nd Update

4 mar 2026, 07:45 UTC

Utili

Bayer Net Loss Widens on Weedkiller Litigation Charges -- Update

4 mar 2026, 07:09 UTC

Utili

Bayer Net Loss Widens on Weedkiller Litigation Charges

6 mag 2026, 06:34 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 mag 2026, 06:33 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 mag 2026, 06:33 UTC

Acquisizioni, Fusioni, Takeovers

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 mag 2026, 06:32 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Pay $300M Upfront

6 mag 2026, 06:32 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 mag 2026, 06:31 UTC

Acquisizioni, Fusioni, Takeovers

Bayer to Buy Perfuse Therapeutics

6 mag 2026, 06:30 UTC

Acquisizioni, Fusioni, Takeovers

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 apr 2026, 14:41 UTC

Utili

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 apr 2026, 14:24 UTC

Discorsi di Mercato

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

16 mar 2026, 14:28 UTC

Discorsi di Mercato

Bayer Edging Closer to Litigation Resolution -- Market Talk

5 mar 2026, 07:03 UTC

Discorsi di Mercato

Bayer's Roundup Settlement Isn't a Done Deal Yet -- Market Talk

4 mar 2026, 12:52 UTC

Discorsi di Mercato

Utili

Bayer Sees Pharma Business Turning a Corner -- Market Talk

4 mar 2026, 12:41 UTC

Discorsi di Mercato

Bayer Expects Consumer Sales to Remain Under Pressure in U.S., China -- Market Talk

4 mar 2026, 12:13 UTC

Discorsi di Mercato

Bayer Expects Challenging Agriculture Market in 2026 -- Market Talk

4 mar 2026, 10:18 UTC

Azioni calde

Stocks to Watch Wednesday: CrowdStrike, Gitlab, Moderna, Strategy, Coinbase -- WSJ

4 mar 2026, 08:32 UTC

Discorsi di Mercato

Utili

Bayer Beats Expectations, But Currency Headwinds Cloud Outlook -- Market Talk

4 mar 2026, 06:41 UTC

Utili

Bayer: Paul Achleitner and Colleen Goggins Won't Stand for Re-election at 2026 AGM

4 mar 2026, 06:41 UTC

Utili

Bayer Proposes Marcel Smits and Alfred Stern as Supervisory Board Members

4 mar 2026, 06:40 UTC

Utili

Bayer Proposes Two New Candidates for Supervisory Board

4 mar 2026, 06:40 UTC

Utili

Bayer: 2026-End Net Debt Expected at EUR32B to EUR33B

4 mar 2026, 06:39 UTC

Utili

Bayer Sees 2026 Free Cash Outflow of EUR1.5B-EUR2.5B Due to Litigation Payouts

4 mar 2026, 06:39 UTC

Utili

Bayer: 2025 Core EPS Would Have Been EUR4.57 Under New Methodology

4 mar 2026, 06:38 UTC

Utili

Bayer: Changing the Way it Calculates Core EPS

4 mar 2026, 06:38 UTC

Utili

Bayer Sees 2026 Core EPS at EUR4.30-EUR4.80

4 mar 2026, 06:37 UTC

Utili

Bayer Sees 2026 Ebitda Before Special Items of EUR9.6B to EUR10.1B

Confronto tra pari

Modifica del prezzo

Bayer AG Previsione

Obiettivo di Prezzo

By TipRanks

29.31% in crescita

Previsioni per 12 mesi

Media 47.82 EUR 29.31%

Alto 56 EUR

Basso 25 EUR

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bayer AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Bayer AG - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

22.99 / 23.88Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

412 / 439 Classifica in Finanza

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.